- Companies
- Abeona Therapeutics
Abeona Therapeutics Valuation Multiples
Abeona Therapeutics is valued at $319M as of September 2026, a 4.6x revenue multiple. In the last 12 months, Abeona Therapeutics revenue was $42M.
Abeona Therapeutics Overview
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Founded
1974
HQ
Employees
136
Website
Financials (LTM)
EV
$192M
Valuation Multiples
Start free trialAbeona Therapeutics Financials
Abeona Therapeutics reported last 12-month revenue of $42M.
In the same LTM period, Abeona Therapeutics generated $31M in gross profit and had net loss of ($18M).
Revenue (LTM)
Abeona Therapeutics P&L
In the most recent fiscal year, Abeona Therapeutics reported revenue of $6M and EBITDA of ($75M).
Abeona Therapeutics is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of (1283%), and net margin of 1223%.
Financial data powered by Morningstar, Inc.
Abeona Therapeutics Stock Performance
Abeona Therapeutics has current market cap of $319M, and enterprise value of $192M.
Market Cap Evolution
Abeona Therapeutics' stock price is $5.57.
Abeona Therapeutics share price decreased by 4.9% in the last 30 days, and increased by 7.8% in the last year.
Abeona Therapeutics has an EPS (earnings per share) of $1.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $192M | $319M | 0.0% | -4.9% | -9.9% | 7.8% | $1.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbeona Therapeutics Valuation Multiples
Abeona Therapeutics trades at 4.6x EV/Revenue multiple, and (2.6x) EV/EBITDA.
EV / Revenue (LTM)
Abeona Therapeutics Financial Valuation Multiples
As of September 20, 2026, Abeona Therapeutics has market cap of $319M and EV of $192M.
Abeona Therapeutics has a P/E ratio of (17.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abeona Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Abeona Therapeutics Margins & Growth Rates
Abeona Therapeutics grew revenue by 859% but net profit decreased by 174% in the last fiscal year.
In the most recent fiscal year, Abeona Therapeutics reported gross margin of 41%, EBITDA margin of (1283%), and net margin of 1223%.
Abeona Therapeutics Margins
Abeona Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Operational KPIs
Abeona Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Competitors
Abeona Therapeutics competitors include SAB Bio, Lavipharm, Medy-Tox, Q32 Bio, GC Biopharma, Ildong Pharmaceutical, Animalcare Group, Vanda Pharmaceuticals, Julphar and AprilBio.
Most Abeona Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | $15M | - | - | 14.6x | (2.8x) | |||
| $72M | $17M | 4.8x | - | 20.7x | - | |||
| $179M | $19M | 2.1x | 2.0x | 19.9x | 14.3x | |||
| $54M | $29M | 4.0x | 13.9x | 7.3x | (9.6x) | |||
| $1.8B | $87M | 1.2x | - | 24.1x | - | |||
| $410M | $47M | 0.9x | 0.9x | 7.8x | - | |||
| $121M | $24M | 2.7x | 2.7x | 13.6x | 13.6x | |||
| $216M | ($127M) | 0.8x | 0.7x | (1.3x) | - | |||
This data is available for Pro users. Sign up to see all Abeona Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abeona Therapeutics
| When was Abeona Therapeutics founded? | Abeona Therapeutics was founded in 1974. |
| Where is Abeona Therapeutics headquartered? | Abeona Therapeutics is headquartered in United States. |
| How many employees does Abeona Therapeutics have? | As of today, Abeona Therapeutics has over 136 employees. |
| Who is the CEO of Abeona Therapeutics? | Abeona Therapeutics' CEO is Vishwas Seshadri. |
| Is Abeona Therapeutics publicly listed? | Yes, Abeona Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Abeona Therapeutics? | Abeona Therapeutics trades under ABEO ticker. |
| When did Abeona Therapeutics go public? | Abeona Therapeutics went public in 1980. |
| Who are competitors of Abeona Therapeutics? | Abeona Therapeutics main competitors include SAB Bio, Lavipharm, Medy-Tox, Q32 Bio, GC Biopharma, Ildong Pharmaceutical, Animalcare Group, Vanda Pharmaceuticals, Julphar, AprilBio. |
| What is the current market cap of Abeona Therapeutics? | Abeona Therapeutics' current market cap is $319M. |
| What is the current revenue of Abeona Therapeutics? | Abeona Therapeutics' last 12 months revenue is $42M. |
| What is the current revenue growth of Abeona Therapeutics? | Abeona Therapeutics revenue growth (NTM/LTM) is 146%. |
| What is the current EV/Revenue multiple of Abeona Therapeutics? | Current revenue multiple of Abeona Therapeutics is 4.6x. |
| Is Abeona Therapeutics profitable? | No, Abeona Therapeutics is not profitable. |
| What is the current net income of Abeona Therapeutics? | Abeona Therapeutics' last 12 months net income is ($18M). |
| How many companies Abeona Therapeutics has acquired to date? | Abeona Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Abeona Therapeutics has invested to date? | Abeona Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Abeona Therapeutics
Lists including Abeona Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




